Literature DB >> 16402100

Cannabinoid pharmacology: the first 66 years.

Roger G Pertwee1.   

Abstract

Research into the pharmacology of individual cannabinoids that began in the 1940s, several decades after the presence of a cannabinoid was first detected in cannabis, is concisely reviewed. Also described is how this pharmacological research led to the discovery of cannabinoid CB(1) and CB(2) receptors and of endogenous ligands for these receptors, to the development of CB(1)- and CB(2)-selective agonists and antagonists and to the realization that the endogenous cannabinoid system has significant roles in both health and disease, and that drugs which mimic, augment or block the actions of endogenously released cannabinoids must have important therapeutic applications. Some goals for future research are identified.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16402100      PMCID: PMC1760722          DOI: 10.1038/sj.bjp.0706406

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

Review 1.  A historical overview of chemical research on cannabinoids.

Authors:  R Mechoulam; L Hanus
Journal:  Chem Phys Lipids       Date:  2000-11       Impact factor: 3.329

Review 2.  The biosynthesis, fate and pharmacological properties of endocannabinoids.

Authors:  V Di Marzo; L De Petrocellis; T Bisogno
Journal:  Handb Exp Pharmacol       Date:  2005

3.  A PHYSIOLOGICALLY ACTIVE PRINCIPLE FROM CANNABIS SATIVA (MARIHUANA).

Authors:  A J Haagen-Smit; C Z Wawra; J B Koepfli; G A Alles; G A Feigen; A N Prater
Journal:  Science       Date:  1940-06-21       Impact factor: 47.728

4.  Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.

Authors:  Adèle Thomas; Lesley A Stevenson; Kerrie N Wease; Martin R Price; Gemma Baillie; Ruth A Ross; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

Review 5.  Pharmacology of cannabinoid CB1 and CB2 receptors.

Authors:  R G Pertwee
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

6.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

Review 7.  Pharmacological actions of cannabinoids.

Authors:  R G Pertwee
Journal:  Handb Exp Pharmacol       Date:  2005

Review 8.  Human studies of cannabinoids and medicinal cannabis.

Authors:  P Robson
Journal:  Handb Exp Pharmacol       Date:  2005

Review 9.  Pharmacology of cannabinoid receptor ligands.

Authors:  R G Pertwee
Journal:  Curr Med Chem       Date:  1999-08       Impact factor: 4.530

Review 10.  Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids.

Authors:  Laura J Sim-Selley
Journal:  Crit Rev Neurobiol       Date:  2003
View more
  169 in total

1.  Cannabinoid CB1 receptors transactivate multiple receptor tyrosine kinases and regulate serine/threonine kinases to activate ERK in neuronal cells.

Authors:  George D Dalton; Allyn C Howlett
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties.

Authors:  Jose Cumella; Laura Hernández-Folgado; Rocio Girón; Eva Sánchez; Paula Morales; Dow P Hurst; Maria Gómez-Cañas; Maria Gómez-Ruiz; Diana C G A Pinto; Pilar Goya; Patricia H Reggio; María Isabel Martin; Javier Fernández-Ruiz; Artur M S Silva; Nadine Jagerovic
Journal:  ChemMedChem       Date:  2012-02-02       Impact factor: 3.466

Review 3.  Blurred boundaries: the therapeutics and politics of medical marijuana.

Authors:  J Michael Bostwick
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

4.  Cannabinoid Inheritance Relies on Complex Genetic Architecture.

Authors:  Lesley G Campbell; Jaimie Dufresne; Sarah A Sabatinos
Journal:  Cannabis Cannabinoid Res       Date:  2020-02-27

5.  AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Authors:  Mark D Black; Rachel J Stevens; Nancy Rogacki; Robert E Featherstone; Yaw Senyah; Odessa Giardino; Beth Borowsky; Jeanne Stemmelin; Caroline Cohen; Philippe Pichat; Michal Arad; Segev Barak; Amaya De Levie; Ina Weiner; Guy Griebel; Geoffrey B Varty
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

6.  Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.

Authors:  Abir T El-Alfy; Kelly Ivey; Keisha Robinson; Safwat Ahmed; Mohamed Radwan; Desmond Slade; Ikhlas Khan; Mahmoud ElSohly; Samir Ross
Journal:  Pharmacol Biochem Behav       Date:  2010-03-21       Impact factor: 3.533

Review 7.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

Review 8.  Medical Cannabis for Older Patients.

Authors:  Amir Minerbi; Winfried Häuser; Mary-Ann Fitzcharles
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

9.  In vivo effects of CB2 receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints.

Authors:  J J McDougall; V Yu; J Thomson
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

Review 10.  Cancer pain management: what's new?

Authors:  Jan Gaertner; Christine Schiessl
Journal:  Curr Pain Headache Rep       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.